Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aticaprant - Johnson & Johnson Innovative Medicine

Next Previous
Drug Profile

Aticaprant - Johnson & Johnson Innovative Medicine

Alternative Names: AVTX-501; CERC 501; JNJ-3964; JNJ-67953964; JNJ-67953964-AAA; LY-2456302

Latest Information Update: 08 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Avalo Therapeutics; Eli Lilly and Company; Johnson & Johnson Innovative Medicine
  • Class Antidepressants; Antipsychotics; Benzamides; Benzene derivatives; Drug withdrawal therapies; Fluorinated hydrocarbons; Pyrrolidines; Small molecules; Smoking cessation therapies
  • Mechanism of Action Opioid kappa receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia
  • Discontinued Alcoholism; Cocaine-related disorders; Major depressive disorder; Smoking withdrawal

Most Recent Events

  • 02 Mar 2026 Phase-I clinical trials in Schizophrenia (Adjunctive treatment) in USA (PO) (NCT07615426)
  • 30 May 2025 Janssen Research & Development terminates a phase III VENTURA-7 trial for Major depressive disorder (Adjunctive treatment) in USA (PO, Tablet), due to sponsor decision (NCT06514742)
  • 25 Apr 2025 Janssen Research & Development terminates a phase III VENTURA-5 trial for Major depressive disorder (Adjunctive treatment) in USA, Argentina, Belgium, Brazil, Bulgaria, France, Germany, Greece, Mexico, Poland, Romania, Spain and Turkey (PO, Tablet) due tosponsor decision (NCT06635135) (EudraCT 2024-511057-22-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top